NovMetaPharma has identified excellent anti-inflammatory and anti-fibrotic efficacies in NovFS (fibrosis medication) cell and animal testing. This confirmed the possibility of developing NovFS as fibrosis medication, and based on this, NovMetaPharma is conducting joint R&D of NovFS.
Decrease of major mechanism gene expression causing idiopathic pulmonary fibrosis
Decrease of mediator genes (ECM) causing idiopathic pulmonary fibrosis
1H 2020 | 2H 2020 | 1H 2021 | 2H 2021 | 1H 2022 | 2H 2022 | |
---|---|---|---|---|---|---|
Substance: cGMP level | License Out (E) |
특허구분 | IP Protection | ||||
---|---|---|---|---|---|
Substance patent (US) |
Application
2019
|
Registration
2020
|
Patent expiration (expected) year
2039
|
||
Fibrosis prevention and improvement patent (KR) |
Application·Registration
2020
|
Patent expiration (expected) year
2040
|